Semaglutide Dosing Calculator, Protocols, and Dosage Chart

Semaglutide is the once-weekly GLP-1 drug behind Ozempic and Wegovy. It usually produces less weight loss than tirzepatide, but it carries the longest outcomes record in the class: fewer heart events in SELECT, slower kidney decline in FLOW, and years of diabetes-trial safety data. That record is the reason to reach for it, and it is the reason the right dose depends on the job.

Two things get lost in the headlines. The first is what a higher dose buys. Going from the 0.25 mg starter to 2.4 mg is close to a tenfold jump, and it does buy more effect, more dose meaning more weight loss. But the reason is not the one most summaries give, and it changes how you titrate; the next section unpacks it. The second is that a single milligram number can mean different things: 1.0 mg is a weak weight-loss dose but the proven kidney dose in type 2 diabetes. So the useful question is not "what is the strongest dose" but "what is the lowest dose that does my job, and how fast can I climb to it without the gut running ahead."

This page is built around that. Weight loss is the job for most readers, so it comes first, with the doses and the trial cohorts that produced them. The other jobs semaglutide has real data for (heart, kidney, blood sugar, and maintenance) follow. The reconstitution math and syringe-unit charts are near the end.

How to Read a Semaglutide Dose

More dose does mean more effect on semaglutide. The widely repeated line that its ladder is "not a strength dial" is wrong, and getting this right is the single most useful thing to understand before choosing a dose.

Across the ladder, the number of receptors carrying a drug molecule climbs about six-fold from the starter dose to the top, and the weight effect climbs right alongside it. Dose scales the effect. What confuses people is a real but separate fact: a single fresh receptor is already firing near its maximum even at the lowest dose, because the receptor reaches full output at only about 10% engagement, and a normal meal uses just 1-4% (receptor-saturation data¹⁸). Read that as a snapshot of one fresh receptor, not the whole story.

The whole story is that semaglutide is held at a steady level, week after week, and never lets the receptor rest. Under that constant exposure the receptor gets pulled off the cell surface and quiets down over time, using the receptor's own built-in off-switch, which semaglutide flips fully (receptor desensitization¹⁸). So what a higher dose really buys is more signal held up against that fade: more dose, more sustained signal against the quieting, more effect. That is why the appetite quiet creeps back at a fixed dose until you step up, and it is the mechanism under the whole titration ladder.

The figure below draws the two lines that get confused. A fresh receptor's signal runs high and nearly flat from the starter dose to the top; the weight effect climbs steeply over the same range. The flat line is the snapshot. The climbing line is the drug.

Three practical rules fall out of that gap. The starter dose is pharmacologically real, not a placebo step; even sub-label exposure beat placebo for weight loss in early trials¹³. The 2.4 mg maintenance dose sits on the shoulder of the effect curve, not a plateau, which is why higher doses still add weight loss in trials. And because the cost climbs on the same curve as the effect, you titrate by tolerance rather than by a target date: if the last step's nausea has not eased, the dose keeps working while you hold, so there is no penalty for waiting.

Weight Loss: The Default Job

STEP 1 is the anchor, and it is one instrument, not a universal number. It enrolled about 1,960 non-diabetic adults with a mean body weight of 105 kg, a BMI of 38, roughly three-quarters women, and an average age of 46. In that cohort, 2.4 mg weekly produced about 15% body-weight loss over 68 weeks, with a wide responder spread: 86% reached at least 5% loss, 69% reached 10%, half reached 15%, and about a third reached 20%¹. Read the cohort into the number. A lighter body, a man, or an older user sits lower on this same instrument for reasons the Different Bodies section makes concrete; the mean is a starting point to translate, not a promise.

What most people notice first is not the scale. It is the quiet. The constant background pull toward food, what users call "food noise," tends to drop within the first week or two, often before the weight moves at all. That is the appetite-suppression mechanism arriving ahead of the visible result, and it is the effect people most often describe as the reason the drug feels different from willpower.

Semaglutide loses less than tirzepatide head-to-head — about 14% versus 20% in SURMOUNT-5². The STEP 1 scan put semaglutide's loss at roughly 62% fat to 38% lean by mass, which reads worse than tirzepatide's roughly 75:25, but the kilogram ratio hides two things the newer data corrected⁵. Lean mass rose as a proportion of total body mass, the drop overstates true muscle because hydration and organ mass sit inside the scan number, and the one functional readout that exists, grip strength, improved on semaglutide¹⁸. The point stays practical: protein and resistance training protect strength during any large loss, and strength is the number to watch, not the scan.

Wegovy and Ozempic Dose Schedule

The Wegovy weight-loss ladder is 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg weekly. Each step normally holds at least 4 weeks, because a new dose takes about 4 to 5 weeks to reach full strength on semaglutide's roughly 7-day half-life, and full washout after the last dose takes about 5 weeks⁷.

Ozempic uses a related diabetes ladder that ends lower: 0.25 -> 0.5 -> 1.0 -> 2.0 mg weekly, with 2.0 mg as a blood-sugar ceiling rather than the Wegovy obesity ceiling. Throughout either ladder, do not climb through unresolved side effects: if nausea, vomiting, constipation, reflux, or food aversion from the prior step has not settled, hold. Most discontinuation happens during titration, not after someone has stabilized at a tolerated dose¹.

What Semaglutide Feels Like, Start to Plateau

The experience is not a straight line, and knowing its shape ahead of time is most of what keeps people from quitting in week two or panicking at the week-six stall. The dose ladder is also a clock: you climb on a schedule, so each step up re-runs a smaller version of the first week. The sections below are what users describe going through, week by week and step by step. They are patterns from real-world reports, not trial incidence rates, and they are most useful as a map of what is normal versus what warrants a pause.

What does appetite suppression feel like on semaglutide?

For most people the first change is not the scale. It is the quiet. The constant background chatter about food, the mid-afternoon pull toward the pantry, the plan-the-next-meal-while-eating-this-one loop, what users call "food noise," drops within the first days to two weeks, often on the 0.25 mg starter and before any weight moves. People describe forgetting to eat lunch, getting full three bites into a plate they would have finished, and losing interest in the sweet or greasy foods that used to be automatic. This is the effect that makes semaglutide feel different from a diet: the wanting is turned down, so eating less does not take willpower.

The quiet is real and it is not permanent at a fixed dose. As the body adapts to each step, some appetite comes back, which is the reason the schedule keeps climbing. You step up, the quiet deepens, then partly fades again over the following weeks, and the cycle repeats until you reach a dose you hold. By the maintenance dose the suppression settles into a durable but milder floor, not the week-one silence. Food noise creeping back at a steady dose is adaptation and usually the signal to step up, not the drug quitting on you and not a reason to jump the ladder faster than the gut can follow.

The side-effect arc, in felt terms

The nausea most people fear is front-loaded and it tracks the injection. For many it is worst in the day or two after the shot and eases across the week, worst of all in the week after each dose increase, then quiet once the dose holds. The rest of the picture is the part the label underplays, and naming it is most of the value here. Constipation is the effect people are least warned about; it builds slowly over weeks as everything moves through slower, and it is worth getting ahead of with fluid, fiber, and movement before it becomes the reason someone quits. Sulfur or rotten-egg burps show up for a subset and are unpleasant but not dangerous. A fatigue dip is common, usually clustered in the first weeks and at the fastest-loss stretch when intake is lowest. Reflux and a heavy, over-full feeling after small meals are routine.

At the peak-loss stretch, two cosmetic effects get their own worry-searches. Hair shedding a couple of months into rapid loss is usually telogen effluvium, the temporary shed that follows any large or fast weight loss rather than a direct drug toxicity, and it recovers. The gaunt "ozempic face" is fat leaving the face along with everywhere else, visible sooner in older or leaner faces; it is loss, not damage. Some people also describe an emotional flatness alongside the food quiet, a dimming of reward that is not only about food. It is reported often enough to name, thinly studied, and worth raising rather than dismissing.

One caution about reading side-effect numbers at all. Trials under-report what users feel, because passive trial reporting catches a fraction of the lived rate, and a trial only records what it decided in advance to measure. A symptom you have that is not on the label (temperature changes and chills, hair shedding, sulfur burps, low mood) is not disproven by its absence from the trial table. The trial measured what it pre-specified; your experience is a different instrument reading the same drug. The two are reconciled by naming which one produced which number, not by treating the trial's silence as evidence the effect is not real.

What to expect at each phase

The expectations that keep people on the drug

Weight does not come off in a line. The scale stalls for weeks while the tape measure and the clothes keep moving, because water shifts and body-composition changes do not show up on the scale day to day. The stall around month two or three is the single most common point where people quit, and it is normal, not a sign the drug stopped working. Food noise returning is adaptation and step-up territory, not failure. The plateau is the destination, not the drug failing you; reaching a lower weight you can hold on a steady dose is what success looks like. And success feels like indifference to food, not misery. If you are white-knuckling through constant hunger, the dose or the drug is wrong for you, not your resolve. The fear of stopping is well-founded but often misread: the weight returns because the underlying biology is unchanged, not because you failed, which is why the landing (a maintenance dose, protein, and resistance training) gets planned before the drug comes off, not after the regain starts (Coming Off, below).

The structural reason the good and the bad arrive together

Tirzepatide carries a second receptor (GIP) that, among other things, buffers nausea, so it can push harder for less proportional gut cost. Semaglutide has no such buffer, so its wanted effect and its side effects ride the same GLP-1R exposure, and titration time is the only tool that separates them. The trial data show the adaptation cleanly: in STEP 4's run-in, 47% of participants had nausea during escalation, and once the dose was held at 2.4 mg, maintenance-phase nausea fell to 14% on the same drug and dose⁴. The receptor engagement did not change; the body adapted. Bring the dose up slowly enough that tolerance catches up before the next step, and expect a held or missed dose to re-open the burden, because restarting at the maintenance dose can feel like the escalation phase again.

Skin dysesthesia is one signal that has since made it onto the label. The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else¹⁹.

Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug¹⁹. The mechanism is unsettled: the tempting "it is the drug's signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal. It is usually mild and reversible, and it eases when the dose comes down.

Different Bodies See Different Doses

Fixed milligram dosing does not put the same drug level in every body. Body weight is the one covariate that meaningfully moves semaglutide exposure, and it moves it inversely: a lighter body sees more drug per milligram.

At the same dose, a 74 kg user sees about 1.4 times the exposure of a 110 kg reference, while a 143 kg user sees about 0.8 times¹². That does not mean the dose should be set by weight, but it explains why lighter and leaner users often feel a low dose as "too much" while heavier users feel little at the starter, and it is why the STEP 1 mean does not transfer cleanly to a body the trial did not enroll.

Two body types shift the weight-loss job specifically. In type 2 diabetes, weight loss runs about a third lower at the same dose (STEP 2 produced about -10% at 2.4 mg versus -15% in STEP 1) for two reasons that stack: diabetes lowers exposure by about 15%, and chronic high blood sugar blunts the downstream response¹⁰. And lean, metabolically healthy users sit outside every efficacy trial; the read is that they will be exposure-elevated and side-effect-forward with less weight to lose, but no trial measured a 15% result for them.

Routine care lands below the trial, too. In a real-world cohort, six-month semaglutide loss was about 8.8%, roughly 0.6 to 0.8 of the STEP figure, mostly through adherence and persistence rather than a weaker drug¹⁵. Read the trial number as a ceiling to translate down toward your own body and your own consistency, not as a forecast.

Heart, Kidney, and Blood Sugar: Where the Record Lives

The same drug does different jobs at different doses, and the evidence is attached to specific doses. This is where semaglutide's maturity shows, and where a single milligram number stops meaning one thing.

Cardiovascular risk runs on the 2.4 mg dose. SELECT enrolled about 17,600 adults with obesity and established cardiovascular disease but no diabetes, and semaglutide 2.4 mg cut major adverse cardiovascular events by 20% over roughly 40 months³. That is a secondary-prevention result in a cohort that already had heart disease, not a general heart-health claim, and it belongs to the full obesity dose.

Kidney protection runs on the 1.0 mg dose. FLOW tested semaglutide 1.0 mg in type 2 diabetes with chronic kidney disease and slowed the progression of kidney damage by about 24%¹⁴. Read the mismatch: 1.0 mg is a weak dose for weight loss, but it is the proven dose for the kidney in that population. A user chasing weight who lands on 1.0 mg is under-dosed for that goal, while a user with diabetic kidney disease has a trial telling them exactly what 1.0 mg buys.

Blood-sugar control saturates below the weight dose. The Ozempic and SUSTAIN glycemic ladder runs 0.25 -> 0.5 -> 1.0 -> 2.0 mg weekly, and HbA1c falls where it starts high. But the glucose effect tops out early: in SUSTAIN FORTE, doubling from 1.0 to 2.0 mg added only about 0.23 points of HbA1c and about 0.9 kg of weight beyond 1.0 mg¹¹. For glucose alone, more milligrams buy little; the extra dose is mostly buying weight.

The FoxAI demo below is built on this exact split, the difference between reciting the label ceilings and telling you what your dose does for your goal.

Coming Off and Maintenance

Semaglutide manages weight; it does not reset the biology that defends it. The plateau on continuous dosing is a balance point, not a failure: appetite stays suppressed while resting energy expenditure falls with the lost mass, and unlike the multi-receptor drugs, semaglutide has no glucagon arm to hold expenditure up against that decline. So the plateau is the goal state at a lower weight, held as long as the drug continues.

Stopping is where the weight returns. Across GLP-1 trials, the off-drug regain follows a predictable curve — roughly 75% of the lost weight comes back at the asymptote, about 60% within the first year, with the fastest regain in the early months and about a quarter of the loss held²¹. STEP 1's own extension sits on that curve: about two-thirds of the lost weight returned within a year of stopping⁶. This is the biology of removing a satiety drug after major weight loss, not a willpower story.

Two paths lead down, and they differ. The gentler one is not fully stopping. Once a plateau is reached, a lower maintenance dose holds most of the loss with less burden: 1.0 mg kept most of the 2.4 mg weight effect in STEP 2, and 0.5 mg has years of use behind it¹⁰ ¹¹. Small real-world series suggest even reduced-frequency dosing can hold a plateau, consistent with the receptor math, where holding a plateau needs less signal than reaching one. The corpus does not yet support a specific step-down protocol, but the direction is clear: taper toward the lowest dose that holds, rather than stopping outright.

The full stop is the other path, and it needs a landing. Protein at roughly 1.6 g/kg/day if tolerated and progressive resistance training belong in from the start, because lean mass is already lower and strength is the number that matters more than the scale. A practical taper runs 8 to 12 weeks at each lower step, not because the receptor needs weaning but because the transition needs support. Reinitiation after a full stop is unstudied for weight trajectory: real-world data show how often people restart, but no trial tracks whether a second course reaches the same low point.

Compounded Semaglutide and Reconstitution

Branded Ozempic and Wegovy pens hide the math. Vial-based semaglutide is different: the vial holds a fixed number of milligrams, and the BAC water volume sets the concentration. The total drug does not change; only the draw volume does. Product access and compounding rules shift over time, so verify source, sterility, concentration, and current rules before any vial-based dosing under clinician supervision¹⁶ ¹⁷.

The per-vial BAC water and syringe-unit charts for the 2.5, 5, and 10 mg vials are below; the full mixing walkthrough lives on the reconstitution calculator.

How to Reconstitute Semaglutide

Oral Semaglutide: Rybelsus Equivalence

Rybelsus is semaglutide taken by mouth with an absorption enhancer that carries it across the stomach lining (SNAC¹²). The molecule is the same, but the exposure is not. Oral absorption is low and variable, so the rules are strict: take it on an empty stomach with no more than 4 oz of plain water, then wait at least 30 minutes before food, drink, or other oral medication.

The common shortcut "14 mg oral equals 1.0 mg injectable" runs too high. Published steady-state exposure puts 14 mg oral daily closer to a 0.5 mg weekly injection, and even 25 mg oral daily lands near a 0.9 mg weekly injection — short of Wegovy 2.4 mg¹².

Switching routes is an exposure change, not a brand swap. A user moving from 14 mg Rybelsus to 1.0 mg Ozempic is stepping up, not matching.

FAQ

Related Topics

• Semaglutide Deep Dive - mechanism, outcomes, trial data, and side-effect depth
• Tirzepatide Dosing - the stronger weight-loss and body-composition comparator
• Retatrutide Dosing - investigational triple-agonist dosing
• GLP-1 Lean Mass - protein and resistance-training protocol
• Stopping GLP-1s - cross-compound stopping and maintenance framework
• Peptide Reconstitution Calculator - all-peptide sterile handling, storage, and calculator basics

References

¹ Wilding JPH, Batterham RL, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021. STEP 1 - non-diabetic obesity trial at 2.4 mg; responder ladder; DXA composition; AE profile.

² Aronne LJ, et al. "Tirzepatide versus semaglutide for obesity." N Engl J Med. 2025. SURMOUNT-5 - head-to-head; -20.2% vs -13.7% at 72 weeks.

³ Lincoff AM, Brown-Frandsen K, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." N Engl J Med. 2023. SELECT - 20% reduction in major adverse cardiovascular events at 2.4 mg.

⁴ Rubino D, et al. STEP-4: continued weekly semaglutide vs placebo switch for weight maintenance. JAMA. 2021. DOI 10.1001/jama.2021.3224 - run-in nausea 47% falling to 14% at maintenance; withdrawal regain.

⁵ STEP-1 DXA body-composition substudy. PMC8089287 - about 62:38 fat-to-lean by derived denominator; lean proportion of total mass rose.

⁶ Wilding JPH, et al. STEP-1 extension: weight trajectory 1 year after withdrawal of semaglutide. Diabetes Obes Metab. 2022. DOI 10.1111/dom.14725 - about two-thirds regain within a year.

⁷ Dhillon S. "Semaglutide: a review in type 2 diabetes and obesity." Drugs. 2021. PMID 33296025 - half-life and pharmacology.

⁸ GLP-1 receptor agonists and gallbladder/biliary disease risk meta-analysis. JAMA Intern Med. Article

⁹ Rubino DM, et al. STEP-8: semaglutide 2.4 mg vs liraglutide 3.0 mg for weight management. JAMA. 2022. DOI 10.1001/jama.2022.0470

¹⁰ Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes." Lancet. 2021. STEP-2 - 1.0 mg vs 2.4 mg dose comparison; T2D attenuation.

¹¹ Frías JP, et al. "Once-weekly semaglutide 2.0 mg versus 1.0 mg in type 2 diabetes." Lancet Diabetes Endocrinol. 2021. SUSTAIN-FORTE - glycemic saturation above 1.0 mg.

¹² Ozempic FDA label §12.3, Wegovy FDA label §12.3, Rybelsus FDA label §12.3; Carlsson Petri et al. 2018 Diabetes Ther. Carlsson 2018 - body-weight exposure covariate; oral-vs-injection exposure; SNAC absorption.

¹³ O'Neil PM, et al. Semaglutide compared with liraglutide and placebo for weight loss in obesity. Lancet. 2018. DOI 10.1016/S0140-6736(18)31773-2 - phase 2 daily-injection dose finding; sub-label activity.

¹⁴ Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024. FLOW - kidney-outcomes benefit at 1.0 mg.

¹⁵ Le Roux CW, et al. Real-world tirzepatide vs semaglutide in non-diabetic obesity. J Endocrinol Invest. 2026;49:413-423 - routine-care cohort, semaglutide arm n=1,393, -8.8% at 6 months.

¹⁶ FDA. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." 2025. FDA statement

¹⁷ FDA. "FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list." 2026. FDA statement

¹⁸ Semaglutide receptor-engagement model - PeptideFox semaglutide explainer, Chapter 6. Binding occupancy climbs about six-fold (roughly 7% to 42%) across the ladder and tracks the weight effect; a fresh receptor's output saturates below about 10% surface engagement (Gao 2023), so its near-flat acute signal is a snapshot, not the dose-response. Under continuous weekly exposure the receptor desensitizes: semaglutide is a full beta-arrestin recruiter (GLP-1R Emax 106%, Coskun 2022 Table S2; corroborated by Oostdyk 2024) and downregulates surface GLP-1R within 12 hours at physiological albumin (Hinds 2024), so the sustained signal held against that fade, set by dose, is what carries the effect. Potency and PK anchors: Lau 2015 (cAMP EC50 6.2 pmol/L), Boianelli 2024 (free fraction 0.36%), FDA 2021 (weight-change EC50 54.6 nmol/L). Grip-strength readout from SEMALEAN real-world DXA.

¹⁹ Frey C, et al. "Risk of allodynia with GLP-1 agonists." medRxiv 2026 (preprint) - adjusted HR 2.15 (1.57-2.96) vs bupropion-naltrexone; STEP UP dose-arm dysesthesia 0.5 / 6 / 22.9%; FDA added dysesthesia to injectable semaglutide labeling, January 2025.

²⁰ Bezin J, et al. "GLP-1 receptor agonists and the risk of thyroid cancer." Diabetes Care. 2023;46:384-390 - adjusted HR 1.58 (1.27-1.95) at 1-3 years; corroborated by Silverii 2025 RCT meta-analysis (OR 1.55) on a small absolute base.

²¹ Budini, et al. GLP-1 receptor agonist weight-regain meta-regression. eClinicalMedicine 2026 - asymptotic regain about 75% of lost weight, roughly 60% by 52 weeks, half-life about 23 weeks.

²² Wang, et al. GLP-1 weight-loss medications, depression, and suicidality: a FAERS disproportionality study. J Affect Disord. 2025;389:119670 - reporting signal confined to the 2023-2024 media surge, with completed-suicide reporting below expected; low-resolution instrument, not incidence.